
==== Front
Am Heart J Plus
Am Heart J Plus
American Heart Journal Plus: Cardiology Research and Practice
2666-6022
Elsevier

S2666-6022(24)00088-0
10.1016/j.ahjo.2024.100445
100445
Research Paper
Public health and system approach in eliminating disparities in hypertensive disorders and cardiovascular outcomes in non-Hispanic Black women across the pregnancy life course
Bond Rachel M. Rachel.bond@dignityhealth.org
a⁎
Bello Natalie A. NatalieAnn.Bello@cshs.org
b
Ansong Annette aansong@childrensnational.org
c
Ferdinand Keith C. kferdina@tulane.edu
d
a Women's Heart Health, Dignity Health, Arizona, 3240 S Mercy Road Suite 312, Gilbert, AZ 85287, United States of America
b Smidt Heart Institute, Cedars Sinai Medical Center, 127 S San Vincente BLVD Suite A3100, Los Angeles, CA 90048, United States of America
c Children's National Hospital, 111 Michigan Avenue, NW, Washington, DC 20010, United States of America
d John W. Deming Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, #8548, New Orleans, LA 70112, United States of America
⁎ Corresponding author. Rachel.bond@dignityhealth.org
28 8 2024
10 2024
28 8 2024
46 10044526 11 2023
4 8 2024
11 8 2024
© 2024 The Authors. Published by Elsevier Inc.
2024

https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Hypertension is one of the leading risk factors for cardiovascular disease. The ACC/AHA/Multisociety hypertension guideline covered all aspects of the recommendations for optimal blood pressure diagnosis and management to improve cardiovascular outcomes. Despite this, there remains a growing prevalence of hypertension within the United States, largely in non-Hispanic Black women at earlier stages of their life course. This highlights the evident racial disparities, but offers a targeted opportunity for improved outcomes. With hypertension increasingly seen in the antenatal and immediate postpartum period, and obstetrics societies weighing in on the need to alter pharmacotherapy initiation goals, national initiatives have purposefully targeted pregnant and postpartum women in an effort to improve outcomes. This same energy must also re-focus health care efforts across the entire health continuum. Public health and system strategies are in place to do so, with the strongest enforcing initiatives as early as childhood with a greater focus on primordial prevention.

Keywords

Maternal health
Health disparities
Social determinants of health
Cardioobstetrics
Black women
Life course
==== Body
pmc1 Introduction

In the United States (US), hypertension (HTN) prevalence is higher in non-Hispanic Black (NHB) women than Hispanic or non-Hispanic White (NHW) women [1]. Similarly, in women of childbearing age, rates of hypertensive disorders of pregnancy (HDP) such as chronic (HTN that precedes pregnancy or occurs prior to 20 weeks gestation) and gestational HTN (de novo hypertension after 20 weeks of gestation) and/or preeclampsia are highest among NHB women, and are increasing [[2], [3], [4]]. Hypertension is the most commonly encountered comorbidity by obstetricians, and is a leading cause of severe maternal morbidity (SMM) [5], and mortality [[6], [7], [8]]. Rates of SMM and mortality [5] have been steadily increasing in the US over the past several decades. This trend is in direct opposition to both global trends in maternal health resulting in a decline in maternal mortality by more than a third from 2000 to 2017, and dramatic advances in perinatal care reducing infant morbidity and mortality worldwide (Fig. 1).Fig. 1 Eliminating disparities in hypertensive disorders and cardiovascular outcomes in Black women across the pregnancy life course.

Fig. 1

In light of these disparities in the US, national initiatives including the Million Hearts 2027 have targeted pregnant and postpartum women with HTN [9]. Such efforts are in place to prevent the short- and long-term adverse pregnancy outcomes (APOs). Nevertheless, current endeavors have proven to be suboptimal and SMM and mortality rates continue to climb. This review will discuss potential solutions from public health and system approaches that may be more beneficial by focusing on primordial care and viewing health through the scope of the life course.

2 Preconception: disparities in offspring born to mothers with HDP

2.1 In-utero to adolescence

The primary focus of HDP has been on the mother and her future risk for cardiovascular disease (CVD) [10,11]. Women with a history of HDP are two times as likely to suffer from CVD 10–15 years after childbirth [12,13]. This same concern and advocacy should be extended to the fetus, infant and child born to mothers with HDP [2,14].

It is well studied that HTN and its related outcomes disproportionately affect NHB adults [15,16]. The same can be said for NHB children, with a 29 % increased odds of HTN compared to their NHW counterparts. Comparably, NHB infants have a higher prevalence of low birthweight (LBW), and obesity [17]. With LBW the leading cause of infant mortality, the infant mortality rate is 2.3 times higher in NHB than NHW infants; and hence NHB infants are 4 times more likely to die from LBW and its complications than NHW infants [14,[18], [19], [20]].

The direct manifestations of preeclampsia on the fetus and newborn include preterm delivery, intrauterine growth restriction (IUGR), placental abruption, and stillbirth. The morbidities for an infant born prematurely or IUGR can be dire and may result in a prolonged hospitalization in the neonatal intensive care unit [21,22].

On a granular level, preeclampsia has been noted to cause an increase in oxidative stress biomarkers, possibly impacting endothelial cell dysfunction [21,23]. The oxidative stress seen may be carried into the fetus. In addition to an increase in free radicals and decrease in antioxidants, there may be increased cholesterol, triglycerides, low density lipoprotein and lowered high density lipoprotein perhaps suggestive of the proatherogenic state initiated in neonates and a potential reason for their risk of developing CVD [21,24].

Several studies have shown that the offspring of mothers with HDP have a tendency to become hypertensive adults [25,26]. The ‘Barker hypothesis’ demonstrates that LBW infants have higher rates of CVD, diabetes and chronic kidney disease in adulthood. This may occur from adjustments that the fetus undergoes due to undernourishment from placental insufficiency [22,[27], [28], [29]].

A population-based study of Nordic infants followed from 1973 to 2014 looked over 5.8 million singleton live births, where 218,322 infants (3.76 %) were born to mothers with HDP. Of these, there was an increased likelihood of stroke (33 %) and heart disease (29 %) with a risk that lasted up to 41 years of age [30]. This highlights the vigilance required in including the obstetrical history of the mothers as part of the routine history of pediatric patients to help identify those children who may be at risk for future cardiac events. It appears increasingly evident that HDP is not a disease that simply appears in pregnancy but is connected to risk factors, many of which are modifiable before and after pregnancy that must be addressed [31].

2.2 Women of reproductive age

Though the factors causing preeclampsia are not fully elucidated, being aware of and optimizing as many of the identified contributing factors is key to a hospitable intrauterine environment for the fetus. Such risk factors include a prior maternal history of HDP, conception utilizing artificial reproductive technology, multifetal gestation, or diabetes. Use of aspirin for women at high risk of developing preeclampsia is advised starting between 12 and 28 weeks gestation through delivery [32]. Practitioners should especially be on high alert when treating NHB women as they are at greater risk of developing preeclampsia and experiencing maternal and infant mortality. The totality of the Black maternal health crisis must in fact include its effects on the fetus, newborn, and child.

3 Disparities in HDP

There are persistent racial disparities in maternal outcomes experienced by NHB women [6,7,[33], [34], [35], [36], [37], [38], [39], [40]]. In 2020, NHB women encountered 55.3 maternal deaths per 100,000 live births compared to 18.2 deaths per 100,000 live births to Hispanic and 19.1 deaths per 100,000 live births to NHW women. When examined by age category, NHB women 40 years of age and over experienced 263.1 deaths per 100,000 live births compared to 86.0 and 96.8 per 100,000 live births for Hispanic and NHW women. In women <25 years of age, those rates were 28.8, 11.5, and 7.7 per 100,000 live births for NHB, NHW, and Hispanic women respectively [3].

Cardiovascular diseases are the leading cause of maternal mortality in the US, and many of these deaths are avoidable. Cardiomyopathy, pulmonary embolism, and HDP disproportionately contribute to pregnancy-related deaths in NHB compared to NHW women, respectively accounting for 19.1 %, 11.0 %, and 22.1 % of the Black/White disparity [41]. The heightened rate of SMM and mortality experienced by NHB women persists irrespective of level of education or socioeconomic status (SES) which may in part be due to social determinants of health (SDOH), systemic racism and the cumulative burden of chronic stress and life events in addition to a higher burden of chronic medical conditions like HTN [42], which have historically suboptimal control.

Utilizing the criteria of treatment to <140/90 mmHg, blood pressure (BP) control was achieved in 66.3 % of NHW, 44.7 % of NHB, and 49.9 % Hispanic women [1]. Of the Centers for Disease Control's (CDC) 21 indicators of SMM [43], 10 are potential sequelae of HTN including peripartum cardiomyopathy (PPCM) which disproportionately impact NHB women [6,44]. Cardiomyopathy accounts for >10 % of maternal deaths and is the leading cause of postpartum death [45]. PPCM, is more common in women of African descent with NHB women experiencing more severe left ventricular systolic dysfunction compared to NHW women [46]. In US women with PPCM, there is a more than four-fold higher prevalence of preeclampsia [44]. While not specifically examined in PPCM, race-based disparities in heart failure risk factors, incidence, and prognosis have been extensively documented and likely contribute to the disproportionately higher rates of maternal mortality experienced by NHB women [47].

4 Postpartum disparities related to HTN

The postpartum period represents a critical window to initiate targeted interventions to improve cardiometabolic health following pregnancies complicated by HDP. Despite evidence-informed guidelines, population data demonstrate that postpartum screening rates and interventions of women who manifest such conditions remain suboptimal and vary substantially, with marked racial/ethnic disparities.

4.1 Postpartum hypertension

In the US, HDP account for approximately 7 % of maternal mortality, with approximately 70 % of these deaths occurring postpartum [45]. Unfortunately, data continue to demonstrate only 13.7 % of women diagnosed with a HDP, disorders including eclampsia, preeclampsia, which may be superimposed on chronic hypertension, and gestational hypertension, attend BP screening within 10 days of delivery, despite recommendations to do so [48]. BP typically declines immediately after delivery and then rises, peaking between 3 and 7 days postpartum [49]. Having close outpatient follow-up is essential to identify and treat HTN and prevent adverse effects. Data from the Pregnancy Risk Assessment Monitoring System (PRAMS), a surveillance system of the CDC and state health departments, suggest wide racial/ethnic disparities exist in the percent of women who attend a postpartum care visit, with one of the greatest disparities noted in NHB women [50]. With the incidence of de novo postpartum hypertension or preeclampsia, HDP occurring up to 42-days postpartum, ranging from 0.3 % to 27.5 % [51], ensuring access to appropriate postpartum follow-up is necessary. Delayed recognition, and subsequent lack of early treatment is associated with an increased risk of readmissions in our healthcare system due to SMM, particularly from eclampsia [52].

With postpartum HTN the leading cause of repeat hospitalization after childbirth, identifying risk factors for readmission is important. These include advanced age, SES, chronic comorbidities, multiple gestation, cesarean delivery, and other high-risk pregnancy conditions [[53], [54], [55]]. Maternal race has proven to be a major risk factor for APOs, with associated disparities in overall risk for severe morbidity and mortality [56]. More recently, a cross-sectional analysis demonstrated that NHB women were more likely to be readmitted postpartum, to suffer SMM during readmission including greater rates of preeclampsia with severe features (43.3 % vs 10.0 % non-Black, p = 0.01), and to suffer life threatening complications including pulmonary edema/acute heart failure [7]. NHB women with cardiometabolic risk factors may benefit from targeted short-term postpartum follow-up.

4.2 Post-child bearing hypertensive disorders

Oftentimes, pregnancy provides a window into an individual's future cardiovascular (CV) health. It is well-established that women with HDP have increased risk of subsequent APOs and a four times greater risk of chronic HTN and two times greater risk of CVD [57]. With untreated HTN leading to a range of disabling and potentially fatal chronic illnesses, the postpartum period is a critical time when CV lifestyle changes should be reinforced and cardiometabolic risk factors optimized for interconception or post-child bearing health [58]. The American College of Obstetricians and Gynecologists (ACOG) has released guidelines recommending that postpartum care is an ongoing process, with services and support tailored to each woman's individual needs [59]. With nearly 58 % of NHB women in the US having HTN compared to about 41 % of NHW and Hispanic women [60], targeted efforts may be appropriate to reinforce this ongoing care.

5 Practical solutions & guidelines to combat disparities in hypertensive disorders of pregnancy

Despite multi-society statements and guidance, there are no clear universal guidelines on how best to manage HDP as a means to combat disparities. An important consideration in optimizing maternal care is characterizing one's risk at every stage of the health continuum and improving access to, and quality of care in the most marginalized risk groups.

6 Lifespan approach

Numerous studies have demonstrated that primordial prevention can positively influence one's lifetime health [61]. As such, re-defining how we view health through a life course lens highlights the potential to improve maternal and infant outcomes for the entire US population [62].

Well-known factors contributing to poor and disparate maternal health outcomes in the US include SDOH centered on psychosocial stressors such as multigenerational structural racism [37]. These conditions increase the risk of common cardiometabolic risk factors such as obesity, chronic HTN and diabetes which negatively impact maternal and CV health outcomes [63]. NHB women have one of the highest prevalence of these risk factors [60], with many beginning at early stages of their life course. As such, focusing efforts to optimize care beginning as early as childhood can be one novel approach to combat APOs. Pediatricians and pediatric subspecialists can do so by screening for these risk factors as early as indicated. Pediatric providers must be attuned to recognizing aberrancies in history, physical exams and lab work that may bring a CV risk factor to the forefront. Providers must highlight the importance of children making it to their routine well-child check visits where BP should be checked, typically beginning at the age of 3 years. As mentioned earlier, the role of the maternal and infant birthing history is key and should be standardized into the history and physical exam. Furthermore, in those with a history of prematurity or LBW, it may be reasonable to consider the BP checked sooner than 3 years of age [64,65]. Once risk factors are identified, counseling on the role a heart-healthy lifestyle plays is pivotal for improved outcomes. Leading CV organizations, such as the Association of Black Cardiologists (ABC), American College of Cardiology (ACC) and the American Heart Association (AHA) have promoted prevention strategies to decrease the incidence of heart disease [66,67]. Utilizing these tools to focus on primordial prevention, can leave a lasting impact on the health of the child and the health of their potential future offspring.

6.1 Re-challenging the house of medicine by expanding the meaning of cardio-obstetrics

The establishment of the cardio-obstetrics team that provides coordinated healthcare has been effective in lowering CV morbidity and mortality and improving outcomes in women with congenital or acquired heart disease, high risk cardiometabolic factors and/or APOs [68]. Moving beyond its standard concept, and including the integration of primary medical and gynecological care both preconception and postpartum remains essential [69]. Beyond that, the inclusion of the pediatrician and/or pediatric subspecialist can further improve outcomes by focusing on primordial prevention [70].

Several care models exist that incorporate preventive measures to reduce cardiometabolic risk, including weight monitoring, nutritional referral, exercise recommendations, and self-monitored blood pressure (SMBP) screening [71]. As suggested by the 2017 ACC/AHA/Multisociety HTN guideline, SMBP with ambulatory or home BP cuffs is very helpful and practical to obtain out-of-office BP readings [72]. It is for this reason, the use of it should replace auscultatory methods of BP measurement as it provides a more reliable estimate of control at different times across a 24-hour period and allows for timely decisions to be made on management. To this point, its use in the antepartum period has been increasingly promoted [71], including initiatives such as Million Hearts 2027 [9]. To allow for this, Million Hearts 2027, like many efforts, promotes the expansion of Medicaid for SMBP devices.

6.2 Advocacy

To build on Million Hearts 2027 vision, the role of the clinician as an advocate for policy change is pivotal. This includes extending Medicaid coverage to one year postpartum; improving coverage of medications; reinforcing the need for social changes, including addressing food insecurity, access to child care and/or ability to attend both obstetric and pediatric appointments.

Similar advocacy led to the Dept. of Health and Human Services aiming to improve BP control rates above 80 % [1]. With such advocacy, a cautionary tale still remains. The state of California has been a national leader in maternal quality improvement since 2006 when the California Maternal Quality Care Collaborative formed. While SMM and mortality has declined in California, the disparity ratio not only persists but has actually increased from 3.4 to 6.0 from 2008 to 2016 the last year data was publicly available [73]. To date, the drivers of this ratio have not been identified, but it may be that a focus on hospital level interventions targeting clinicians and administrators fails to account for and address the complex socioeconomic and environmental factors underlying health disparities, thus widening the gap. This paradox underlies the need for rigorous evaluation of novel interventions that can also bring healthcare to the people via community-based solutions and ensure their outcomes are achieving the desired impact on health equity.

6.3 Optimize what we know: treatment timing controversies that support tighter BP control

Diagnostic BP treatment thresholds for the general population have evolved. In 2017, the ACC/AHA/Multisociety hypertension guideline lowered the threshold for the diagnosis of stage 1 hypertension to 130/80 mmHg [72]. The decision was based on observational studies and clinical trials demonstrating reduced CV events with treatment to lower levels.

Such a change regarding the threshold for initiation of antihypertensive treatment has been considered controversial for pregnant women due to a lack of certainty of its benefits for this population vs. the potential neonatal risk. Most guidelines agree HTN in pregnancy is defined as BP of ≥140/90 mmHg [74]. Such guidelines, based largely on expert opinions, including ACOG recommend treatment thresholds starting at severe values of ≥160/110 mmHg in the antepartum period and ≥150/100 mmHg in the postpartum period [75].

Although the best treatment thresholds still have yet to be determined for postpartum hypertension, retrospective cohort data remains promising. With that, the use of pharmacotherapy initiation threshold for stage 2 hypertension (140/90 mmHg) in the postpartum period, has shown to significantly improve maternal outcomes and decrease readmissions with no deleterious effect on neonatal outcomes [76]. Researchers most recently evaluated if the same positive effects can be achieved in the antenatal period if using targets for nonpregnant, reproductive-age adults. The Chronic Hypertension and Pregnancy (CHAP) study, included >2400 pregnant participants' randomly assigned labetalol or nifedipine with a treatment goal of <140/90 mmHg or no treatment unless BP is severe in patients with mild chronic HTN [77]. Results demonstrated that in pregnant women with mild chronic HTN, targeting BP of <140/90 mmHg was associated with better pregnancy outcomes, with no increase in the risk of poor neonatal outcomes.

Using the ACC/AHA/Multisociety 2017 guideline for stage 1 has improved the appropriate identification of women who may go on to develop severe HDP and have associated increased risk for adverse fetal/neonatal outcomes [78,79]. As NHB women have a higher incidence of HDP, research is needed to see if these populations would benefit the greatest from modifying the guidelines to suggest more aggressive BP monitoring and treatment thresholds.

6.4 The future direction of removing HDP disparities in care: where do we go from here?

We still do not fully understand the mechanistic cause for preeclampsia. We best understand that it's associated with placental dysfunction, anti-angiogenesis, oxidative stress and inflammation [80], and that there are women at higher risk for developing preeclampsia, such as NHB women. To recognize and best manage, future studies focusing on the epigenetic, transcriptomic aspects of understanding the phenotypes are essential. In the interim, educating the community along with the healthcare professionals on the risks for short- and long-term CVD is necessary and should become the standard of care. As innovative research continues in the cardio-obstetrics arena, there are steps clinicians can take to better identify women at higher risk for HDP during preconception and prenatal care visits. These same steps should be extended well past the postpartum visits.

Such steps may include broad implementation of evidence-based remote monitoring programs, which have the potential to significantly reduce adverse outcomes. A study be Hersbherg, et al [81] nicely illustrates this potential. With such programs comes a much-needed handoff for mothers at greatest risk, particularly women of color, by enabling continuous monitoring and timely intervention. Such interventions may also address in office follow-through, which may be challenging for some patients. However, more research is needed to fully understand the long-terms benefits and optimize these programs' implementation.

To date, the American Academy of Pediatrics (AAP) recommends routine screening for postpartum depression (PPD) in mothers during well-child visits at 1, 2, 4, and 6 months of age [82]. The AAP emphasized the importance of early identification and intervention for mothers with PPD in mitigating the impact on parent-child interaction and social-emotional development, making this screening the standard of care. With the frequency of check-ups coupled with the emerging doctor-family relationship, this recommendation seems rational to be included in well-baby care. Perhaps extending a similar approach by utilizing the pediatrician office to also screen for postpartum HTN is appropriate. Although this also seems logical, this is an area that will require more research and advocacy support.

7 Conclusion

The maternal health crisis of unacceptably high maternal morbidity and mortality is being increasingly recognized, especially racial disparities. Non-Hispanic Black women are dying at disproportionately high rates from largely preventable causes of maternal mortality, including HDP and premature CVD. There must be public health and system approaches in place to eliminate disparities in hypertensive disorders and CV outcomes in NHB women across their life course. Re-focusing health care efforts across the health continuum, starting as early as childhood with a greater focus on primordial and primary prevention is essential.

CRediT authorship contribution statement

Rachel M. Bond: Writing – review & editing, Writing – original draft, Supervision, Conceptualization. Natalie A. Bello: Writing – original draft, Data curation, Conceptualization. Annette Ansong: Writing – original draft, Data curation. Keith C. Ferdinand: Writing – review & editing, Conceptualization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
==== Refs
References

1 Healthy Women, Healthy Pregnancies, Healthy Futures: Action Plan to Improve Maternal Health in America. US Department of Health and Human Services. https://aspe.hhs.gov/sites/default/files/private/aspe-files/264076/healthy-women-healthy-pregnancies-healthy-future-action-plan_0.pdf. 2020. Accessed January 24.
2 Ford N.D. Cox S. Ko J.Y. Ouyang L. Romero L. Colarusso T. Ferre C.D. Kroelinger C.D. Hayes D.K. Barfield W.D. Hypertensive disorders in pregnancy and Mortality at delivery hospitalization - United States, 2017-2019 MMWR Morb. Mortal. Wkly Rep. 71 2022 585 591 10.15585/mmwr.mm7117a1 35482575
3 Hoyert D. Maternal mortality rates in the United States, 2020 NCHS Health E-Stats 2022 Centers for Disease Control and Prevention
4 Cameron N.A. Petito L.C. Shah N.S. Perak A.M. Catov J.M. Bello N.A. Capewell S. O’Flaherty M. Lloyd-Jones D.M. Greenland P. Association of Birth Year of pregnant individuals with trends in hypertensive disorders of pregnancy in the United States, 1995-2019 JAMA Netw. Open 5 2022 e2228093 10.1001/jamanetworkopen.2022.28093
5 Kilpatrick S.K. Ecker J.L. Severe maternal morbidity: screening and review Am. J. Obstet. Gynecol. 215 2016 B17 B22 10.1016/j.ajog.2016.07.050 27560600
6 Miller E.C. Zambrano Espinoza M.D. Huang Y. Friedman A.M. Boehme A.K. Bello N.A. Cleary K.L. Wright J.D. D’Alton M.E. Maternal race/ethnicity, hypertension, and risk for stroke during delivery admission J. Am. Heart Assoc. 9 2020 e014775 10.1161/JAHA.119.014775
7 Aziz A, Gyamfi-Bannerman C, Siddiq Z, Wright JD, Goffman D, Sheen JJ, D'Alton ME, Friedman AM. Maternal outcomes by race during postpartum readmissions. Am. J. Obstet. Gynecol. 2019;220:484 e481–484 e410. doi: 10.1016/j.ajog.2019.02.016.
8 Garovic V.D. Dechend R. Easterling T. Karumanchi S.A. McMurtry Baird S. Magee L.A. Rana S. Vermunt J.V. August P. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association Hypertension 79 2022 e21 e41 10.1161/hyp.0000000000000208 34905954
9 Hearts M. Focusing on Health Equity. US Centers for Disease Control and Prevention, Division for Heart Disease and Stroke Prevention. https://millionhearts.hhs.gov/about-million-hearts/health-equity/index.html. 2022. Accessed 24 Aug.
10 Garovic V.D. White W.M. Vaughan L. Saiki M. Parashuram S. Garcia-Valencia O. Weissgerber T.L. Milic N. Weaver A. Mielke M.M. Incidence and long-term outcomes of hypertensive disorders of pregnancy J. Am. Coll. Cardiol. 75 2020 2323 2334 10.1016/j.jacc.2020.03.028 32381164
11 Blumer V. Pagidipati N.J. Hypertensive disorders of pregnancy and long-term Heart failure risk: a missed opportunity for prevention Hypertension 76 2020 1420 1422 10.1161/HYPERTENSIONAHA.120.15924 33026911
12 Hung S.K. Lee M.S. Lin H.Y. Chen L.C. Chuang C.J. Chew C.H. Yu B.H. Yang H.J. Hsu F.C. Chiou W.Y. Impact of hypertensive disorders of pregnancy on the risk of stroke stratified by subtypes and follow-up time Stroke 53 2022 338 344 10.1161/STROKEAHA.121.034109 34983243
13 Wang Y.X. Arvizu M. Rich-Edwards J.W. Wang L. Rosner B. Stuart J.J. Rexrode K.M. Chavarro J.E. Hypertensive disorders of pregnancy and subsequent risk of premature Mortality J. Am. Coll. Cardiol. 77 2021 1302 1312 10.1016/j.jacc.2021.01.018 33706872
14 Subki A.H. Algethami M.R. Baabdullah W.M. Alnefaie M.N. Alzanbagi M.A. Alsolami R.M. Abduljabbar H.S. Prevalence, risk factors, and fetal and maternal outcomes of hypertensive disorders of pregnancy: a retrospective study in Western Saudi Arabia Oman Med. J. 33 2018 409 415 10.5001/omj.2018.75 30210720
15 Lackland D.T. Racial differences in hypertension: implications for high blood pressure management Am. J. Med. Sci. 348 2014 135 138 10.1097/MAJ.0000000000000308 24983758
16 Ford E.S. Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States Circulation 123 2011 1737 1744 10.1161/CIRCULATIONAHA.110.005645 21518989
17 Chen L. Simonsen N. Liu L. Racial differences of pediatric hypertension in relation to birth weight and body size in the United States PloS One 10 2015 e0132606 10.1371/journal.pone.0132606
18 Infant Mortality and African Americans. Office of Minority Health, U.S. Department of Health and Human Services. https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lvlid=23. 2021. Accessed 2 Sep.
19 Birthweight. March of Dimes. https://www.marchofdimes.org/peristats/data?reg=99&top=4&stop=45&lev=1&slev=1&obj=1. 2022. Accessed 2 Sep.
20 Jaleta D.D. Gebremedhin T. Jebena M.G. Perinatal outcomes of women with hypertensive disorders of pregnancy in Jimma medical center, Southwest Ethiopia: retrospective cohort study PloS One 16 2021 e0256520 10.1371/journal.pone.0256520
21 de Souza Suppo Rugolo L.M. Bentlin M.R. Trindade C.E.P. Preeclampsia: effect on the fetus and newborn NeoReviews 12 2011 e198 e206
22 Cosmi E. Fanelli T. Visentin S. Trevisanuto D. Zanardo V. Consequences in infants that were intrauterine growth restricted J. Pregnancy 2011 2011 364381 10.1155/2011/364381
23 Orhan H. Onderoglu L. Yucel A. Sahin G. Circulating biomarkers of oxidative stress in complicated pregnancies Arch. Gynecol. Obstet. 267 2003 189 195 10.1007/s00404-002-0319-2 12592416
24 Howlader M.Z. Parveen S. Tamanna S. Khan T.A. Begum F. Oxidative stress and antioxidant status in neonates born to pre-eclamptic mother J. Trop. Pediatr. 55 2009 363 367 10.1093/tropej/fmp025 19380372
25 Ediriweera D.S. Dilina N. Perera U. Flores F. Samita S. Risk of low birth weight on adulthood hypertension - evidence from a tertiary care hospital in a south Asian country, Sri Lanka: a retrospective cohort study BMC Public Health 17 2017 358 10.1186/s12889-017-4268-x 28438199
26 Barker D.J. Osmond C. Golding J. Kuh D. Wadsworth M.E. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease BMJ 298 1989 564 567 10.1136/bmj.298.6673.564 2495113
27 Barker D.J. Adult consequences of fetal growth restriction Clin. Obstet. Gynecol. 49 2006 270 283 10.1097/00003081-200606000-00009 16721106
28 Crump C. Sundquist J. Winkleby M.A. Sundquist K. Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study BMJ 365 2019 l1346 10.1136/bmj.l1346
29 Starr M.C. Hingorani S.R. Prematurity and future kidney health: the growing risk of chronic kidney disease Curr. Opin. Pediatr. 30 2018 228 235 10.1097/MOP.0000000000000607 29432217
30 Yang F. Chen H. Wei D. Janszky I. Roos N. Gissler M. Li J. Laszlo K.D. Associations of maternal hypertensive disorders during pregnancy with offspring risks of ischemic heart disease and stroke: a Nordic cohort study Eur. Heart J. 2021 42 10.1093/eurheartj/ehab724.2889
31 Hajar R. Risk factors for coronary artery disease: historical perspectives Heart Views. 18 2017 109 114 10.4103/HEARTVIEWS.HEARTVIEWS_106_17 29184622
32 Force U.S.P.S.T. Davidson K.W. Barry M.J. Mangione C.M. Cabana M. Caughey A.B. Davis E.M. Donahue K.E. Doubeni C.A. Kubik M. Aspirin use to prevent preeclampsia and related morbidity and Mortality: US preventive services task Force recommendation statement JAMA 326 2021 1186 1191 10.1001/jama.2021.14781 34581729
33 Howell E.A. Brown H. Brumley J. Bryant A.S. Caughey A.B. Cornell A.M. Grant J.H. Gregory K.D. Gullo S.M. Kozhimannil K.B. Reduction of Peripartum racial and ethnic disparities: a conceptual framework and maternal safety consensus bundle Obstet. Gynecol. 131 2018 770 782 10.1097/AOG.0000000000002475 29683895
34 Grobman W.A. Bailit J.L. Rice M.M. Wapner R.J. Reddy U.M. Varner M.W. Thorp J.M. Jr. Leveno K.J. Caritis S.N. Iams J.D. Racial and ethnic disparities in maternal morbidity and obstetric care Obstet. Gynecol. 125 2015 1460 1467 10.1097/aog.0000000000000735 26000518
35 Creanga A.A. Bateman B.T. Kuklina E.V. Callaghan W.M. Racial and ethnic disparities in severe maternal morbidity: a multistate analysis, 2008-2010 Am. J. Obstet. Gynecol. 210 435 2014 e431 e438 10.1016/j.ajog.2013.11.039
36 Bryant A.S. Worjoloh A. Caughey A.B. Washington A.E. Racial/ethnic disparities in obstetric outcomes and care: prevalence and determinants Am. J. Obstet. Gynecol. 202 2010 335 343 10.1016/j.ajog.2009.10.864 20060513
37 Petersen E.E. Davis N.L. Goodman D. Cox S. Syverson C. Seed K. Shapiro-Mendoza C. Callaghan W.M. Barfield W. Racial/ethnic disparities in pregnancy-related deaths - United States, 2007-2016 MMWR Morb. Mortal. Wkly Rep. 68 2019 762 765 10.15585/mmwr.mm6835a3 31487273
38 Gyamfi-Bannerman C. Pandita A. Miller E.C. Boehme A.K. Wright J.D. Siddiq Z. D’Alton M.E. Friedman A.M. Preeclampsia outcomes at delivery and race J. Matern. Fetal Neonatal Med. 33 2020 3619 3626 10.1080/14767058.2019.1581522 30786794
39 Gyamfi-Bannerman C, Srinivas SK, Wright JD, Goffman D, Siddiq Z, D'Alton ME, Friedman AM. Postpartum hemorrhage outcomes and race. Am. J. Obstet. Gynecol. 2018;219:185 e181–185 e110. doi: 10.1016/j.ajog.2018.04.052.
40 Booker W.A. Gyamfi-Bannerman C. Sheen J.J. Wright J.D. Siddiq Z. D’Alton M.E. Friedman A.M. Maternal outcomes by race for Women aged 40 years or older Obstet. Gynecol. 132 2018 404 413 10.1097/AOG.0000000000002751 29995723
41 MacDorman M.F. Thoma M. Declcerq E. Howell E.A. Racial and ethnic disparities in maternal Mortality in the United States using enhanced vital records, 20162017 Am. J. Public Health 111 2021 1673 1681 10.2105/AJPH.2021.306375 34383557
42 Admon L.K. Winkelman T.N.A. Zivin K. Terplan M. Mhyre J.M. Dalton V.K. Racial and ethnic disparities in the incidence of severe maternal morbidity in the United States, 2012-2015 Obstet. Gynecol. 132 2018 1158 1166 10.1097/AOG.0000000000002937 30303912
43 How Does CDC Identify Severe Maternal Morbidity? Centers for Disease Control and Prevention. https://www.cdc.gov/reproductivehealth/maternalinfanthealth/smm/severe-morbidity-ICD.htm. 2021. Accessed January 24.
44 Bello N. Rendon I.S.H. Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis J. Am. Coll. Cardiol. 62 2013 1715 1723 10.1016/j.jacc.2013.08.717 24013055
45 Petersen E.E. Davis N.L. Goodman D. Cox S. Mayes N. Johnston E. Syverson C. Seed K. Shapiro-Mendoza C.K. Callaghan W.M. Vital signs: pregnancy-related deaths, United States, 2011-2015, and strategies for prevention, 13 states, 2013-2017 MMWR Morb. Mortal. Wkly Rep. 68 2019 423 429 10.15585/mmwr.mm6818e1 31071074
46 McNamara D.M. Elkayam U. Alharethi R. Damp J. Hsich E. Ewald G. Modi K. Alexis J.D. Ramani G.V. Semigran M.J. Clinical outcomes for Peripartum cardiomyopathy in North America: results of the IPAC study (investigations of pregnancy-associated cardiomyopathy) J. Am. Coll. Cardiol. 66 2015 905 914 10.1016/j.jacc.2015.06.1309 26293760
47 Youmans Q.R. Lloyd-Jones D.M. Khan S.S. Race, ancestry, and risk: targeting prevention to address Heart failure disparities Circ. Heart Fail. 15 2022 e008741 10.1161/CIRCHEARTFAILURE.121.008741
48 Campbell A. Stanhope K.K. Platner M. Joseph N.T. Jamieson D.J. Boulet S.L. Demographic and clinical predictors of postpartum blood pressure screening attendance J Womens Health (Larchmt) 31 2022 347 355 10.1089/jwh.2021.0161 34610249
49 Walters B.N. Walters T. Hypertension in the puerperium Lancet 2 1987 330 10.1016/s0140-6736(87)90912-3
50 Jones E.J. Hernandez T.L. Edmonds J.K. Ferranti E.P. Continued disparities in postpartum follow-up and screening among Women with gestational diabetes and hypertensive disorders of pregnancy: a systematic review J. Perinat. Neonatal Nurs. 33 2019 136 148 10.1097/JPN.0000000000000399 31021939
51 Chames M.C. Livingston J.C. Ivester T.S. Barton J.R. Sibai B.M. Late postpartum eclampsia: a preventable disease? Am. J. Obstet. Gynecol. 186 2002 1174 1177 10.1067/mob.2002.123824 12066093
52 Davis N.L. Smoots A.N. Goodman D.A. Pregnancy-related Deaths: Data From 14 U.S. Maternal Mortality Review Committees, 2008–2017. Atlanta, GA 2019
53 Clapp MA, Little SE, Zheng J, Robinson JN. A multi-state analysis of postpartum readmissions in the United States. Am. J. Obstet. Gynecol. 2016;215:113 e111–113 e110. doi: 10.1016/j.ajog.2016.01.174.
54 Aseltine R.H. Jr. Yan J. Fleischman S. Katz M. DeFrancesco M. Racial and ethnic disparities in hospital readmissions after delivery Obstet. Gynecol. 126 2015 1040 1047 10.1097/AOG.0000000000001090 26444126
55 Sharvit M. Rubinstein T. Ravid D. Shechter-Maor G. Fishman A. Biron-Shental T. Patients with high-risk pregnancies and complicated deliveries have an increased risk of maternal postpartum readmissions Arch. Gynecol. Obstet. 290 2014 629 633 10.1007/s00404-014-3255-z 24800723
56 Creanga A.A. Syverson C. Seed K. Callaghan W.M. Pregnancy-related Mortality in the United States, 2011-2013 Obstet. Gynecol. 130 2017 366 373 10.1097/AOG.0000000000002114 28697109
57 Gastrich M.D. Zinonos S. Bachmann G. Cosgrove N.M. Cabrera J. Cheng J.Q. Kostis J.B. Preeclamptic Women are at significantly higher risk of future cardiovascular outcomes over a 15-year period J Womens Health (Larchmt) 29 2020 74 83 10.1089/jwh.2019.7671 31414929
58 Mehta L.S. Warnes C.A. Bradley E. Burton T. Economy K. Mehran R. Safdar B. Sharma G. Wood M. Valente A.M. Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association Circulation 141 2020 e884 e903 10.1161/CIR.0000000000000772 32362133
59 ACOG Committee Opinion No 736: Optimizing Postpartum Care Obstet. Gynecol. 131 2018 e140 e150 10.1097/AOG.0000000000002633 29683911
60 Virani S.S. Alonso A. Aparicio H.J. Benjamin E.J. Bittencourt M.S. Callaway C.W. Carson A.P. Chamberlain A.M. Cheng S. Delling F.N. Heart disease and stroke Statistics-2021 update: a report from the American Heart Association Circulation 143 2021 e254 e743 10.1161/cir.0000000000000950 33501848
61 Ferdinand K.C. Primordial prevention of cardiovascular disease in childhood: the time is now J. Am. Coll. Cardiol. 73 2019 2022 2024 10.1016/j.jacc.2019.02.024 31023423
62 Bond R.M. Phillips K. Ivy K.N. Ogueri V. Parapid B. Miller S.C. Ansong A. Cardiovascular health of Black Women before, during, and after pregnancy: a call to action and implications for prevention Curr. Cardiovasc. Risk Rep. 2022 10.1007/s12170-022-00703-0
63 Office of the Surgeon G Publications and reports of the surgeon general The Surgeon General’s Call to Action to Improve Maternal Health 2020 US Department of Health and Human Services Washington (DC)
64 Moran C.M. Panzarino V.M. Darden P.M. Reigart J.R. Preventive services: blood pressure checks at well child visits Clin. Pediatr. (Phila) 42 2003 627 634 10.1177/000992280304200709 14552522
65 Pediatrics AAo Screening & Treating Kids for High Blood Pressure: AAP Report Explained HealthyChildren.org https://www.healthychildren.org/English/health-issues/conditions/heart/Pages/High-Blood-Pressure-in-Children.aspx 2017
66 7 Steps to a Healthy Heart, Washington, DC. Association of Black Cardiologists, Inc. https://abcardio.org/galleries/7-steps-to-a-healthy-heart-washington-dc/. 2013. (Accessed 29 Aug).
67 Lloyd-Jones D.M. Allen N.B. Anderson C.A.M. Black T. Brewer L.C. Foraker R.E. Grandner M.A. Lavretsky H. Perak A.M. Sharma G. Life’s essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association Circulation 146 2022 e18 e43 10.1161/CIR.0000000000001078 35766027
68 Sharma G. Zakaria S. Michos E.D. Bhatt A.B. Lundberg G.P. Florio K.L. Vaught A.J. Ouyang P. Mehta L. Improving cardiovascular workforce competencies in cardio-obstetrics: current challenges and future directions J. Am. Heart Assoc. 9 2020 e015569 10.1161/JAHA.119.015569
69 Brown H.L. Warner J.J. Gianos E. Gulati M. Hill A.J. Hollier L.M. Rosen S.E. Rosser M.L. Wenger N.K. American Heart A. Promoting risk identification and reduction of cardiovascular disease in Women through collaboration with obstetricians and gynecologists: a presidential advisory from the American Heart Association and the American College of Obstetricians and Gynecologists Circulation 137 2018 e843 e852 10.1161/CIR.0000000000000582 29748185
70 Bond R.M. Gaither K. Nasser S.A. Albert M.A. Ferdinand K.C. Njoroge J.N. Parapid B. Hayes S.N. Pegus C. Sogade B. Working agenda for Black mothers: a position paper from the Association of Black Cardiologists on solutions to improving Black maternal health Circ. Cardiovasc. Qual. Outcomes 14 2021 e007643 10.1161/CIRCOUTCOMES.120.007643
71 Hauspurg A. Lemon L.S. Quinn B.A. Binstock A. Larkin J. Beigi R.H. Watson A.R. Simhan H.N. A postpartum remote hypertension monitoring protocol implemented at the hospital level Obstet. Gynecol. 134 2019 685 691 10.1097/AOG.0000000000003479 31503166
72 Whelton P.K. Carey R.M. Aronow W.S. Casey D.E. Jr. Collins K.J. Dennison Himmelfarb C. DePalma S.M. Gidding S. Jamerson K.A. Jones D.W. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology/American Heart Association task Force on clinical practice guidelines Hypertension 71 2018 e13 e115 10.1161/HYP.0000000000000065 29133356
73 Krakowiak P, Sun D, Reynen D, Ramos D, Ahmad S, Amian R, Mitchell C, McCain C, Alvarez D, Main EK, et al. CA-PMSS Surveillance Report: Pregnancy-Related Deaths in California, 2008–2016. California department of public health, Maternal, Child and Adolescent Health Division. https://www.cdph.ca.gov/Programs/CFH/DMCAH/surveillance/CDPH%20Document%20Library/CA-PMSS/CA-PMSS-Surveillance-Report-2008-2016.pdf. 2021. Accessed January 11.
74 ACOG Practice Bulletin No 203: chronic hypertension in pregnancy Obstet. Gynecol. 133 2019 e26 e50 10.1097/aog.0000000000003020 30575676
75 Hypertension in pregnancy Report of the American College of Obstetricians and Gynecologists’ task Force on hypertension in pregnancy Obstet. Gynecol. 122 2013 1122 1131 10.1097/01.AOG.0000437382.03963.88 24150027
76 Mukhtarova N. Alagoz O. Chen Y.H. Hoppe K. Evaluation of different blood pressure assessment strategies and cutoff values to predict postpartum hypertension-related readmissions: a retrospective cohort study Am J Obstet Gynecol MFM. 3 2021 100252 10.1016/j.ajogmf.2020.100252
77 Tita A.T. Szychowski J.M. Boggess K. Dugoff L. Sibai B. Lawrence K. Hughes B.L. Bell J. Aagaard K. Edwards R.K. Treatment for mild chronic hypertension during pregnancy N. Engl. J. Med. 386 2022 1781 1792 10.1056/NEJMoa2201295 35363951
78 Wu D.D. Gao L. Huang O. Ullah K. Guo M.X. Liu Y. Zhang J. Chen L. Fan J.X. Sheng J.Z. Increased adverse pregnancy outcomes associated with stage 1 hypertension in a low-risk cohort: evidence from 47 874 cases Hypertension 75 2020 772 780 10.1161/HYPERTENSIONAHA.119.14252 32008433
79 Bello N.A. Zhou H. Cheetham T.C. Miller E. Getahun D.T. Fassett M.J. Reynolds K. Prevalence of hypertension among pregnant Women when using the 2017 American College of Cardiology/American Heart Association blood pressure guidelines and association with maternal and fetal outcomes JAMA Netw. Open 4 2021 e213808 10.1001/jamanetworkopen.2021.3808
80 Steegers E.A. von Dadelszen P. Duvekot J.J. Pijnenborg R. Pre-eclampsia. Lancet. 376 2010 631 644 10.1016/S0140-6736(10)60279-6 20598363
81 Hirshberg, Adi; Zhu, Yifan; Smith-McLallen, Aaron; Srinivas, Sindhu K.. Association of a Remote Blood Pressure Monitoring Program with Postpartum Adverse Outcomes. Obstet. Gynecol. 141(6):p 1163–1170, June 2023.
82 Rafferty J. Mattson G. Earls M.F. Yogman M.W. Committee On Psychosocial Aspects Of C, Family H Incorporating recognition and Management of Perinatal Depression into Pediatric Practice Pediatrics 2019 143 10.1542/peds.2018-3260 31060547
